Compare OABI & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OABI | PROF |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | Canada |
| Employees | 89 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 237.4M | 238.1M |
| IPO Year | N/A | 2017 |
| Metric | OABI | PROF |
|---|---|---|
| Price | $1.42 | $6.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $4.50 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 566.4K | 83.7K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | N/A | ★ 1.41 |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | $52.42 | $92.40 |
| Revenue Next Year | $64.69 | $64.10 |
| P/E Ratio | ★ N/A | $4.79 |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $1.22 | $3.92 |
| 52 Week High | $2.22 | $8.95 |
| Indicator | OABI | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 39.50 | 53.63 |
| Support Level | $1.32 | $5.75 |
| Resistance Level | $1.70 | $7.07 |
| Average True Range (ATR) | 0.09 | 0.39 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 20.00 | 58.14 |
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.